Mexicos extended

FDA has asked Pfizer, Inc. to withdraw Bextra (valdexocib) from the market because the entire risk versus benefit
profile for the drug is unfavorable. FDA has also asked Pfizer to contain a boxed augury in the Celebrex (celecoxib) brand.

The Food and Stimulant Administration (FDA) today announced a series of important changes pertaining to the marketing of the
non-steroidal anti-rabid class of drugs, including COX-2 selective and medication and non-medication
(over-the-counter (OTC)) non-discriminatory NSAID medications. A list of these products is available on the Internet at fda.gov/cder/drug/infopage/cox2/default.htm.

“Today’s actions protect and ahead of the vigour of the millions of Americans who rely on these drugs everyday,” said Dr.
Steven K. Galson, Acting Chairman of FDA’s Center for Drug Evaluation and Probing (CDER). “FDA is providing the out of the closet
information based on the latest at one’s fingertips scientific data to teach the meticulous and appropriate use of these drugs aimed at
maximizing their dormant benefits and minimizing their risks.”

Pfizer has agreed to delay sales and marketing of Bextra in the U.S., pending further discussions with the activity. Pfizer
has agreed to work with FDA on the boxed warning for Celebrex. FDA is asking manufacturers of all other direction NSAIDs
to correct their labels to file the same boxed portent highlighting the hidden for increased risk of cardiovascular (CV)
events and gastrointestinal (GI) bleeding associated with their press into service. Manufacturers of Celebrex and all other prescription
NSAIDs will be asked to revise their labeling to include a Medication Guide for patients to expropriate make them aware of the
potential for CV and GI adverse events associated with the use of this class of drugs.

In additionally, FDA is asking the manufacturers of all OTC NSAIDs to revamp their labels to count more well-defined info
about the capacity CV and GI risks, and poop to assist consumers in the safe use of the drugs. FDA is also asking
manufacturers of OTC NSAIDs to include a warning about potential skin reactions. The labeling of the formula NSAIDs
already addresses potential strip reactions.

This current reexamination of the CV risks of NSAIDs began after Merck conducted a unbidden worldwide withdrawal of its
COX-2 demanding NSAID, Vioxx (rofecoxib), in September 2004. FDA will carefully review any proposal from Merck for resumption
of marketing of Vioxx.

These actions are based on the available scientific details, including figures accumulated since the drugs were approved. The FDA
has carefully considered the presentations, discussions, and recommendations from the dive meeting of the Agency’s Arthritis
and Numb Cover and Risk Management Notice Committee held on February 16-18, 2005.

To inform the catholic and healthcare community of its decisions, FDA today issued a Social Health Admonition (PHA) and updated
compliant and healthcare practitioner inside info sheets.

Additional report more today’s announcements is nearby on FDA’s Web site at http://www.fda.gov/cder. Information can also be obtained by job 1-888-INFO-FDA (888-463-6332).

fda.gov/bbs/topics/news/2005/NEW01171.html

Observation drug word on Bextra; Vioxx.

Recent Articles on Medical: Contra la impotencia.

Farmacia online madrid

The World Salubrity Organization (WHO) and Salubriousness Deportment Oecumenical seeking Africa (HAI Africa) have published reports of findings from medicine price surveys undertaken in 2004 and 2005, using the WHO/HAI price survey methodology.

Data collected on the outlay and availability of medicines in 11 African countries showed that the surveyed medicines were generally expensive, barely available in Mrs Average strength facilities, and, where at one’s disposal in antisocial sector outlets, they were priced beyond the reach of the womanhood of the population.

“Prices of originator brands of medicine rest in reclusive sector outlets were found to be as much as seven times higher than the prices of their generic equivalents,” said Dr Alimata J. Diarra-Nama, Director of Fettle Systems and Services Development at the WHO Regional Purpose for Africa.

She illustrated her point, in the interest example, in complete of the countries surveyed, the lowest paid unskilled guidance working man would have to manage for more than four days to buy from private pharmacies the least expensive version of a month of treatment to treat adolescence asthma.

“Given the low-down that price is a major frontier to access to medicines, the findings of the surveys urge the need for stronger advocacy to overhaul affordability as well as the growth and implementation of appropriate national medicine policies and strategies, Dr Diarra-Nama said.

Generally, the findings of the surveys show a dearth of consistency in the pricing of medicines within regions and sectors in countries, and the duration of fair price variations across countries surveyed.

The dominant survey findings were discussed at several national and inter-country workshops which made recommendations on crucial approaches to make medication prices more affordable. Among these are:

– improving availability of medicines in the public sector;

– promoting generic medication and substitution of medicines;

– improving availability and appropriate handling of generic medicines;

– providing reliable information on medicament prices;

– improving experience of medicine supply and procurement systems;

– undertaking continuous monitoring of procurement and prices paid by patients and regularly providing governments and consumers with up-to-date information on the prices of drug and

– removing import taxes and levies on essential medicines.

PS: The medicament toll evaluate reports for Chad, Ethiopia, Ghana, Kenya, Mali, Nigeria, Senegal, United Republic of Tanzania; Uganda and a multi-country comparison of the Colleague States of the East African Community are contemporarily available at www.afro.who.int/dsd/index.html. Medicine price survey reports from other countries inclination be posted on our website in due movement.

http://www.afro.who.int

Buy dapsone

According to a newly published study being accessible sunset and heyday on your mobile phone may not be such a favourable horror.

Study author Noelle Chesley, an assistant professor of sociology at the University of Wisconsin, suggests that the 24 hour accessibility that cell phones and pagers provide could be adversely affecting people’s lives.

Chesley says it may even have a negative effect on family life.

The study tracked as many as 1,300 adults over a 2 year period and found that those who consistently used a mobile phone or pager throughout the period were more likely to report a negative “spillover” between work and home life, which resulted in a less satisfactory family life.

The term spillover indicates that the line between work and home is blurred, and the one may invade the other.

When this happens job-related calls at home, or household issues at work erode both work time and leisure time.

According to Chesley, this may be especially true for working women who are more likely to suffer from such a scenario as cell phones and pagers mean there is even more opportunity for spillover between work and home.

Men who consistently use mobile phones and pagers were more affected by work issues encroaching on to family time, whereas for women, the spillover worked both ways.

In the study the people who reported more negative spillover were less satisfied with their family life.

Chesley believes cell phones and pagers appear to provide more stressful encounters among families than positive ones.

Chesley suggests that employers might review their policies on contacting employees after-hours in order to ensure they are reasonable, while employees themselves should ensure that cell phones and pagers are switched off during family time.

When it comes to on working mothers, she suggests that parents might take turns to be on call for their family while at work.

The study is published in the Journal of Marriage and Family.

Sexual health charity, The Extraction Planning Association’s (fpa) latest flier, ‘Learning Disabilities, Sex & The Law’
is an updated guide to new and existing legislation regarding sexual activity and people with culture disabilities. It is
written to offer staff who exert oneself with this group speed up-by-out of tune with advice and news about the law and their statutory
obligations and also offers case studies and examples of use practice.

Subjects discussed in the book, authored by Clare Fanstone and Sarah Andrews, incorporate character to concede, intimate care, the
reason of relations workers and contraception. A question is posed to acquaint each thesis which is scrupulously analysed and examined.
There are also helpful signposts for readers who may wish to run down one field in further verse.

Hilary Brown, Professor of Social Care, Canterbury Christ Church University College, writes in the foreword: ‘This book will
lift you to ascend confidently and to use your ‘common sense’ ensuring that the law does not hold good you back but empowers you to
act in the interests of people with learning disabilities, who look to you, and to your advantage, for advice, support and
protection.’

Copies rate £13.99 + p&p and are available from fpa direct on 0845 122 8600 or fpadirect@fpa.org.uk.

Seeking further information telephone fpa’s press office on 020 7923 5202/5201 or mobile 07958 921 060.

Recent Articles on Medical: Remedios contra la impotencia.

fpa (Family Planning Association) is the contrariwise registered charity working to make progress the sexy health and reproductive
rights of all people throughout the UK.

http://www.fpa.org.uk

Farmacias venta on line

Although radiation remedial programme following a mastectomy is known to reduce the risk of breast cancer recurring, the result of radiation group therapy on survival has long been controversial.

There has always been concern regarding the long term health effects of radiation therapy, in particular regarding the heart.

A new study has found that for breast cancer patients who have undergone a mastectomy, radiation therapy improves survival but only when the dose is appropriate and the target area is sufficient.

At present the accepted approach to radiation therapy is thought to minimize the exposure to the heart, and it is expected that the currently accepted doses and broad target areas will show survival benefits.

It has been suggested that previous studies which failed to find a survival benefit of radiation therapy did not take into account the quality of the radiation therapy provided.

In order to assess the relationship between post-mastectomy radiation therapy and survival, the researchers conducted an analysis of 38 clinical trials.

All of the studies enrolled women with operable breast cancer that was first treated by mastectomy, and each study compared radiation therapy to no radiation therapy. The studies involved a total of 13,199 women.

The quality of radiation therapy administered in each trial was classified into 3 categories:

Optimal radiation therapy, where the radiation dose was 40-60 Gy in 2-Gy fractions administered to the chest wall, the axillary lymph nodes, and the area right above the collarbone.

Category 2: Inadequate or excessive radiation therapy, where the dose was below 40 Gy or above 60 Gy.

Category 3: Incomplete tissue coverage, where the radiation was administered to an area smaller than the chest wall and regional lymph nodes.

In the category 1 studies radiation therapy improved survival by 6.4%.over 10 years.

In the category 2 and category 3 studies radiation therapy did not significantly improve 10-year survival.

The risk of the cancer recurring was also evaluated and it was found that radiation therapy reduced the risk of recurrence to a greater extent in category 1 studies than in category 2 or category 3 studies.

The researchers concluded that radiation therapy given in an appropriate dose to an adequately large area of the body improves survival for up to 10 years.

The results are published in the Journal of the National Cancer Institute.